SPG Blocks for Headaches

• Status: Recruiting
• Trial end date: 2021-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This will be a single-center, open-label clinical trial comparing sphenopalatine ganglion blocks to standard intravenous therapy for patients who come to the emergency department for a headache.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kendall Healthcare Group, Ltd.
• Collaborator: Nova Southeastern University
• Treatments: Prochlorperazine

Criteria

Inclusion Criteria:

• Any patient at least 18 years old who presented to the ED with a suspected primary headache.

Exclusion Criteria:

• pregnant women

• prisoners

• meningeal signs

• fever

• any acute abnormality on neurologic exam

• allergy to one of study drugs

• on oral anticoagulant

• already received analgesic treatment in the ED